Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT02026843
Recruiting Observational

Analysis of Biomarkers From Patients With Chorioretinal Diseases

NCT02026843 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kyungpook National University Hospital
Phase
Observational
Started
2012-04
Last updated
2025-03-06

Condition(s) studied

Diabetic RetinopathyMacular Degeneration

Investigational drug(s) / intervention(s)

Chorioretinal diseases

Chorioretinal diseases: chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Study summary

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Eligibility

Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * age over 20 years * patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity. * patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. * control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders. Exclusion Criteria: * under the age of 20 years * patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor * patients that did not signed the informed consent of the trial * patients with intraocular inflammations or infections that requiring any pharmaceutical agent * patients with recent ocular trauma

Primary outcome measure(s)

  • Biomarkers in ocular fluids — one month
    To establish if certain type of chorioretinal diseases group are associated to different concentrations of gene or protein concentration.

Trial sites (1)

FacilityCityRegionStatus
Dong Ho Park Daegu Kyungsangpookdo Recruiting

More Kyungpook National University Hospital trials in South Korea

The Treatment Effect for Asymptomatic Common Bile Duct Stone Recruiting
Early Commencement of Adjuvant Chemotherapy for Colon Cancer Active, not recruiting
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer Active, not recruiting
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer Active, not recruiting
Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk Recruiting

Other trials for the same condition

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 Active, not recruiting
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02026843 on ClinicalTrials.gov ↗ ← All trials in South Korea